NCT05207787 - Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

306

Participants

Timeline

Start Date

November 9, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2025

Conditions

Solid Tumor

Interventions

DRUG

HS-10365

Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Chest Hospital, Shanghai